Last reviewed · How we verify
WCK 771 IV Infusion
WCK 771 IV Infusion is a Small molecule drug developed by Wockhardt. It is currently in Phase 1 development.
At a glance
| Generic name | WCK 771 IV Infusion |
|---|---|
| Sponsor | Wockhardt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771 (PHASE1)
- Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WCK 771 IV Infusion CI brief — competitive landscape report
- WCK 771 IV Infusion updates RSS · CI watch RSS
- Wockhardt portfolio CI
Frequently asked questions about WCK 771 IV Infusion
What is WCK 771 IV Infusion?
WCK 771 IV Infusion is a Small molecule drug developed by Wockhardt.
Who makes WCK 771 IV Infusion?
WCK 771 IV Infusion is developed by Wockhardt (see full Wockhardt pipeline at /company/wockhardt).
What development phase is WCK 771 IV Infusion in?
WCK 771 IV Infusion is in Phase 1.
Related
- Manufacturer: Wockhardt — full pipeline
- Compare: WCK 771 IV Infusion vs similar drugs
- Pricing: WCK 771 IV Infusion cost, discount & access